<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-29T06:45:20Z</responseDate><request verb="GetRecord" identifier="oai:repisalud.isciii.es:20.500.12105/18169" metadataPrefix="mets">https://repisalud.isciii.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:repisalud.isciii.es:20.500.12105/18169</identifier><datestamp>2024-11-28T15:50:03Z</datestamp><setSpec>com_20.500.12105_15322</setSpec><setSpec>com_20.500.12105_2051</setSpec><setSpec>col_20.500.12105_16927</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_20.500.12105-18169" TYPE="DSpace ITEM" PROFILE="DSpace METS SIP Profile 1.0" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:20.500.12105/18169">
   <metsHdr CREATEDATE="2026-04-29T08:45:20Z">
      <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
         <name>Repisalud</name>
      </agent>
   </metsHdr>
   <dmdSec ID="DMD_20.500.12105_18169">
      <mdWrap MDTYPE="MODS">
         <xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
            <mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Bogas, Gador</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Mayorga, Cristobalina</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Martín-Serrano, Ángela</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fernández-Santamaría, Rubén</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Jiménez-Sánchez, Isabel M.</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Ariza, Adriana</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Barrionuevo, Esther</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Posadas, Teresa</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Salas, María</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fernández, Tahía Diana</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Torres, María José</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Montañez, María Isabel</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">authoraffiliation</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>[Bogas,G; Mayorga,G; Martín-Serrano,A; Fernández-Santamaría,R; Jiménez-Sánchez,IM; Ariza,A; Barrionuevo,E; Posadas,T; Salas,M; Fernández,TD; Torres,MJ; Montañez,MI] Allergy Research Group, Instituto de Investigación Biomédica de Málaga- IBIMA, Hospital Civil, Málaga, Spain. [Bogas,G; Mayorga,G; Barrionuevo,E; Posadas,T; Salas,M; Torres,MJ] Allergy Unit, Hospital Regional Universitario de Málaga, Hospital Civil,  Málaga, Spain. [Mayorga,G; Martín-Serrano,A; Jiménez-Sánchez,IM; Torres,MJ; Montañez,MI] Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain. [Fernández,TD] Departamento de Biología Celular, Genética y Fisiología, Universidad de Málaga, Málaga, Spain. [Torres,MJ] Departamento de Medicina, Universidad de Málaga, Facultad de Medicina, Málaga, Spain.</mods:namePart>
               </mods:name>
               <mods:extension>
                  <mods:dateAccessioned encoding="iso8601">2024-02-12T19:48:15Z</mods:dateAccessioned>
               </mods:extension>
               <mods:extension>
                  <mods:dateAvailable encoding="iso8601">2024-02-12T19:48:15Z</mods:dateAvailable>
               </mods:extension>
               <mods:originInfo>
                  <mods:dateIssued encoding="iso8601">2020-12-04</mods:dateIssued>
               </mods:originInfo>
               <mods:identifier type="other">http://hdl.handle.net/10668/3574</mods:identifier>
               <mods:identifier type="uri">http://hdl.handle.net/20.500.12105/18169</mods:identifier>
               <mods:identifier type="pubmedID">33292516</mods:identifier>
               <mods:identifier type="doi">10.1186/s13601-020-00368-1</mods:identifier>
               <mods:identifier type="e-issn">2045-7022</mods:identifier>
               <mods:identifier type="journal">Clinical and Translational Allergy</mods:identifier>
               <mods:abstract>Background: Analysis of cross-reactivity is necessary for prescribing safe cephalosporins for penicillin allergic patients. Amoxicillin (AX) is the betalactam most often involved in immediate hypersensitivity reactions (IHRs), and cefadroxil (CX) the most likely cephalosporin to cross-react with AX, since they share the same R1 side chain, unlike cefuroxime (CO), with a structurally different R1. We aimed to analyse cross-reactivity with CX and CO in patients with confirmed IHRs to AX, including sIgE recognition to AX, CX, CO, and novel synthetic determinants of CX. Methods: Fifty-four patients with confirmed IHRs to AX based on skin test (ST) and/or drug provocation test (DPT) were included. Serum sIgE to AX and benzylpenicillin was determined by Radioallergosorbent test (RAST). Two potential determinants of CX, involving intact or modified R1 structure, with open betalactam ring, were synthesised and sIgE evaluated by RAST inhibition assay. Results: Tolerance to CX (Group A) was observed in 64.8% cases and cross-reactivity in 35.2% cases (Group B). Cross-reactivity with CO was only found in 1.8% cases from Group B. ST to CX showed a negative predictive value of 94.6%. RAST inhibition assays showed higher recognition to CX as well as to both synthetic determinants (66% of positive cases) in Group B. Conclusions: Cross-reactivity with CX in AX allergic patients is 35%, being ST not enough for prediction. R1, although critical for recognition, is not the unique factor. The synthetic determinants of CX, 1-(HOPhG-Ser-Bu) and 2-(pyrazinone) are promising tools for determining in vitro cross-reactivity to CX in AX allergic patients. Background: Betalactams (BLs) are the drugs most frequently involved in immediate (IgE-mediated) hypersensitivity reactions (IHRs) [1,2,3], which could be explained by their ability to act as haptens due to their high chemical reactivity against proteins [4, 5]. BL chemical structure is formed by a 4-membered ring (the so-called BL ring) that in penicillins is fused to a 5-membered thiazolidine ring, and in cephalosporins to a 6-membered dihydrothiazine ring (Fig. 1). These drugs have a side chain (R1) bound to the BL ring; besides, cephalosporins have a second side chain (R2) bound to the dihydrothiazine ring, whose chemical structures distinguish the different compounds [6, 7].</mods:abstract>
               <mods:language>
                  <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
               </mods:language>
               <mods:accessCondition type="useAndReproduction"/>
               <mods:subject>
                  <mods:topic>Amoxicillin</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Betalactam</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Cephalosporin</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Cross-reactivity</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Drug allergy</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Antigenic determinant</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Specific IgE</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Amoxicilina</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Beta-lactamas</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Cefalosporinas</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Hipersensibilidad a las Drogas</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Reacciones cruzadas</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Epítopos</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Inmunoglobulina E</mods:topic>
               </mods:subject>
               <mods:titleInfo>
                  <mods:title>Penicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes</mods:title>
               </mods:titleInfo>
               <mods:genre>research article</mods:genre>
            </mods:mods>
         </xmlData>
      </mdWrap>
   </dmdSec>
   <structMap LABEL="DSpace Object" TYPE="LOGICAL">
      <div TYPE="DSpace Object Contents" ADMID="DMD_20.500.12105_18169"/>
   </structMap>
</mets></metadata></record></GetRecord></OAI-PMH>